Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.

出版年份 2022 全文链接

标题

作者

关键词

出版物

JOURNAL OF CLINICAL ONCOLOGY

Volume 40, Issue 16_suppl, Pages 8042-8042

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2022-06-07

DOI

10.1200/jco.2022.40.16_suppl.8042

向作者/读者发起求助以获取更多资源

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

JOURNAL OF CLINICAL ONCOLOGY

向作者/读者发起求助以获取更多资源

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Discover Peeref hubs